Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RELIEVE UCCD phase 2b study of TEV-48574 in ulcerative colitis or Crohn's disease
MOH_2023-10-16_000656Phase 2Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Jul 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of duvakitug in autoimmune colitis and Crohn's disease (4 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoints: Clinical remission induction in ulcerative colitis at week 14 and Endoscopic response in Crohn's disease at week 14. Started Jul 2023; status: completed.
02
Drugs
duvakitug
03
Conditions
autoimmune colitisCrohn's disease
Beyond the preview
Go deeper on MOH_2023-10-16_000656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-10-16_000656.